AVEO Pharmaceuticals Investor Relations Material

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in finding, acquiring, developing and commercializing novel cancer therapeutics for patients. The company´s lead anti-cancer candidate, Tivozanib, is an oral pan-targeted receptor tyrosine kinase inhibitor that AVEO believes may offer therapeutic benefits to adult patients with various types of cancer, including kidney cancer, breast cancer and colon cancer. The company is also developing a biomarker that could enable physicians to identify earlier in treatment those patients who respond favorably or unfavorably to therapy with Tivozanib or other angiogenesis inhibitors.